Omalizumab in patients with severe asthma and persistent sputum eosinophilia

Simple item page
dc.contributor.authorMukherjee, Manali
dc.contributor.authorKjarsgaard, Melanie
dc.contributor.authorRadford, Katherine
dc.contributor.authorHuang, Chynna
dc.contributor.authorLeigh, Richard
dc.contributor.authorDorscheid, Delbert R
dc.contributor.authorLemiere, Catherine
dc.contributor.authorBoulet, Louis-Philippe
dc.contributor.authorWaserman, Susan
dc.contributor.authorMartin, James
dc.contributor.authorNair, Parameswaran
dc.date.accessioned2019-04-07T00:02:47Z
dc.date.available2019-04-07T00:02:47Z
dc.date.issued2019-04-03
dc.date.updated2019-04-07T00:02:46Z
dc.description.abstractAbstract Omalizumab, a recombinant humanized monoclonal antibody targeting the IgE molecule, is the first biologic approved for moderate-to-severe allergic asthmatics, who remain uncontrolled despite high dose inhaled corticosteroid and bronchodilators. Steroid-sparing effect of omalizumab has not been demonstrated in asthmatics with persistent airway eosinophilia in a randomised controlled trial till date. From this double-blind, placebo-controlled, multi-centred, randomized parallel group design, we report that omalizumab is possibly inadequate to control sputum eosinophilia, and therefore may not have a steroid-sparing effect, especially in those maintained on oral corticosteroids daily. This needs to be confirmed or refuted in a larger trial, which may be a challenge with respect to recruitment, since there are currently three additional biologics available to prescribe. Trial registration Clinicaltrials.gov, NCT02049294, Registered 30th January 2014, https://clinicaltrials.gov/ct2/show/NCT02049294
dc.identifier.citationAllergy, Asthma & Clinical Immunology. 2019 Apr 03;15(1):21
dc.identifier.doihttps://doi.org/10.1186/s13223-019-0337-2
dc.identifier.urihttp://hdl.handle.net/1880/110140
dc.identifier.urihttps://doi.org/10.11575/PRISM/45510
dc.language.rfc3066en
dc.rights.holderThe Author(s)
dc.titleOmalizumab in patients with severe asthma and persistent sputum eosinophilia
dc.typeunknown
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
13223_2019_Article_337.pdf
Size:
1.31 MB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
0 B
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Open Access Publications